BIOMAT Database Logo BIOMAT Database Logo

[Maintenance of remission in acute myeloid leukemia by allogeneic or autologous bone marrow transplantation]. 1991

D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Klinik und Poliklinik für Knochenmarktransplantation, Universitätsklinikum Essen.

Over a 10-year period 120 patients (58 women, 62 men; median age 33 [14-53] years) with acute myeloid leukaemia were treated by allogenic (n = 90) or autologous bone marrow transplantation to maintain remission. After a median observation time of 41 (11-126) months 64 patients (53%) remain alive without recurrence of leukaemia. Ten years after allogenic transplantation performed during the first complete remission the probability of disease-free survival is 50 +/- 8%, as compared with 50 +/- 9% at 4.5 years after autologous transplantation. Significant factors influencing disease-free survival after allogenic transplantation during the first complete remission were the time interval up to the onset of remission and the length of the remission before transplantation. The chance of disease-free survival after allogenic transplantation in the second complete remission does not so far differ from the results achieved by transplantation in the first complete remission. The risk of recurrence after autologous transplantation in the first complete remission (47 +/- 10%) is significantly higher than that following allogenic transplantation (18 +/- 10%, P less than 0.0001). Acute graft versus host reactions occurred in 16% and chronic reactions in 36% of patients after allogenic transplantation. The mortality was 38% after allogenic transplantation and 7% after autologous transplantation.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006087 Graft vs Host Reaction An immunological attack mounted by a graft against the host because of HISTOINCOMPATIBILITY when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE. HLA Sensitization,Human Leukocyte Antigen Sensitization,Sensitization, HLA

Related Publications

D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Post-remission treatment in acute myeloid leukemia: chemotherapy or autologous or allogeneic bone marrow transplantation.
January 1990, Haematologica,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission.
January 1981, Haematology and blood transfusion,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
January 1990, Bone marrow transplantation,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission.
April 1991, Bone marrow transplantation,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Autologous bone marrow transplantation in acute myeloid leukemia in relapse or in complete remission.
November 1982, Cancer treatment reports,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
December 1998, The New England journal of medicine,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Allogeneic bone marrow transplantation versus chemotherapy in first-remission acute myeloid leukemia.
July 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
January 2001, Blood,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Chemotherapy versus allogeneic or autologous bone marrow transplantation in second complete remission of acute lymphoblastic leukemia.
November 1992, Leukemia,
D W Beelen, and K Quabeck, and H K Mahmoud, and H G Sayer, and J Kraft, and U Graeven, and H Grosse-Wilde, and U Quast, and U W Schaefer
Intensive chemotherapy versus allogeneic bone marrow transplantation in first-remission acute myeloid leukemia.
July 1990, Bone marrow transplantation,
Copied contents to your clipboard!